Hims Hers Health is trading 4.18% down at $27.41 amid post-earnings concerns over its wider-than-expected second-quarter loss and margin pressure from branded weight-loss drugs.
- The decline comes during a broader August 18, 2026 risk-off session, with the Nasdaq down 1.44% and the S&P 500 down 0.70%.
- Healthcare is outperforming, so sector weakness does not explain the decline.
- Margin pressure from branded weight-loss drugs previously weighed on shares.